Richard Hazen

2.1k citations

36 papers · 1.5k indexed · h-index 20

Co-authors: Joseph Larner Robert G. Ferris Joseph H. Chan Ronald J. Walkenbach Edward P. Garvey Lawrence R. Boone D.K. Stammers Karen R. Romines
Topics: HIV/AIDS drug development and treatment (29 papers)HIV Research and Treatment (22 papers)Biochemical and Molecular Research (10 papers)
Cited by: Virology Infectious Diseases Organic Chemistry
Journals: Biochemical and Biophysical Research Communications Journal of Medicinal Chemistry Antimicrobial Agents and Chemotherapy
Partner nations: United States United Kingdom China

In The Last Decade

Richard Hazen

35 papers receiving 1.4k citations

Peers

Countries citing papers authored by Richard Hazen

Since Specialization

Citations

This map shows the geographic impact of Richard Hazen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Hazen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Hazen more than expected).

Fields of papers citing papers by Richard Hazen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Hazen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Hazen. The network helps show where Richard Hazen may publish in the future.

Co-authorship network of co-authors of Richard Hazen

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Hazen. A scholar is included among the top collaborators of Richard Hazen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Hazen. Richard Hazen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structural Basis for the Improved Drug Resistance Profile of New Generation Benzophenone Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors 2008 ·Journal of Medicinal Chemistry ·Jingshan Ren,Philip P. Chamberlain,Anna Stamp,Steven A. Short,Kurt Weaver,Karen R. Romines,Richard Hazen,Andrew Freeman,Robert G. Ferris,C. Webster Andrews,Lawrence R. Boone,Joseph H. Chan,D.K. Stammers	64
2	In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV 2007 ·Antimicrobial Agents and Chemotherapy ·Richard Hazen,Victoria L. Harvey,Robert G. Ferris,Charles Craig,(unknown),Philip Griffin,John F. Miller,István Káldor,John E. Ray,(unknown),Eric S. Furfine,Andrew Spaltenstein,Michael Hale,Roger D. Tung,Marty St. Clair,Mary H. Hanlon,Lawrence R. Boone	26
3	Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385 2006 ·Bioorganic & Medicinal Chemistry Letters ·John F. Miller,C. Webster Andrews,(unknown),Eric S. Furfine,Michael Hale,Mary H. Hanlon,Richard Hazen,István Káldor,Ed W. McLean,David J. Reynolds,(unknown),Andrew Spaltenstein,Roger D. Tung,Elizabeth M. Turner,Robert X. Xu,Ronald G. Sherrill	70
4	Application of Phosphoramidate ProTide Technology Significantly Improves Antiviral Potency of Carbocyclic Adenosine Derivatives 2006 ·Journal of Medicinal Chemistry ·Christopher McGuigan,(unknown),Sheila Srinivasan,Yikang Wang,(unknown),Susan M. Daluge,Kristjan S. Gudmundsson,Huiqiang Zhou,Ed W. McLean,(unknown),Thimysta C. Burnette,Harry B. Marr,Richard Hazen,Lynn D. Condreay,Lance C. Johnson,Jan Balzarini	51
5	Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1. 2005 ·PubMed ·E. Randall Lanier,Richard Hazen,Lisa Ross,Andrew L. Freeman,Richard J. Harvey	10
6	Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles 2005 ·Bioorganic & Medicinal Chemistry Letters ·John F. Miller,(unknown),Eric S. Furfine,Richard Hazen,István Káldor,David J. Reynolds,Ronald G. Sherrill,Andrew Spaltenstein	15
7	Antiviral Activity of GW678248, a Novel Benzophenone Nonnucleoside Reverse Transcriptase Inhibitor 2005 ·Antimicrobial Agents and Chemotherapy ·Robert G. Ferris,Richard Hazen,(unknown),M H St Clair,Joseph H. Chan,Karen R. Romines,George A. Freeman,Jeffrey H. Tidwell,Lee T. Schaller,Jill R. Cowan,Steven A. Short,Kurt Weaver,Dean W. Selleseth,(unknown),Lawrence R. Boone	51
8	Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors 2005 ·Bioorganic & Medicinal Chemistry Letters ·Ronald G. Sherrill,Eric S. Furfine,Richard Hazen,John F. Miller,David J. Reynolds,(unknown),Andrew Spaltenstein,Pat Wheelan,Lois L. Wright	8
9	Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains 2004 ·Bioorganic & Medicinal Chemistry Letters ·John F. Miller,Eric S. Furfine,Mary H. Hanlon,Richard Hazen,John A. Ray,(unknown),Vicente Sámano,Andrew Spaltenstein	16
10	Phosphoramidate Protides of Carbocyclic 2′,3′‐Dideoxy‐2′,3′‐Didehydro‐7‐Deazaadenosine with Potent Activity Against HIV and HBV 2004 ·Nucleosides Nucleotides & Nucleic Acids ·Kristjan S. Gudmundsson,Zhicheng Wang,Susan M. Daluge,Lance C. Johnson,Richard Hazen,Lynn D. Condreay,Christopher McGuigan	8
11	Optimization of pyrrolidinone based HIV protease inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Ronald G. Sherrill,C. Webster Andrews,(unknown),Ronda G. Davis‐Ward,Eric S. Furfine,Richard Hazen,(unknown),Andrew Spaltenstein,Lois L. Wright	10
12	Novel Benzophenones as Non-nucleoside Reverse Transcriptase Inhibitors of HIV-1 2004 ·Journal of Medicinal Chemistry ·Joseph H. Chan,George A. Freeman,Jeffrey H. Tidwell,Karen R. Romines,Lee T. Schaller,Jill R. Cowan,(unknown),(unknown),C. Webster Andrews,David J. Reynolds,Marty St. Clair,Richard Hazen,(unknown),Katrina L. Creech,(unknown),Steven A. Short,Kurt Weaver,George W. Koszalka,Lawrence R. Boone	52
13	Assessment of the Relative Potency of Emtricitabine and Lamivudine 2003 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Richard Hazen,E. Randall Lanier	2
14	Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening 2002 ·Antiviral Research ·(unknown),Thomas B. Stanley,Richard Hazen,Edward P. Garvey	41
15	Abacavir in Combination With the Inosine Monophosphate Dehydrogenase (IMPDH)–Inhibitor Mycophenolic Acid Is Active Against Multidrug-Resistant HIV-1 1999 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Alonso Heredia,David M. Margolis,David Oldach,Richard Hazen,Nhut Le,Robert Redfield	15
16	Inhibitors of Human Immunodeficiency Virus Type 1 Derived from gp41 Transmembrane Protein: Structure−Activity Studies 1996 ·Journal of Medicinal Chemistry ·Wieslaw M. Kazmierski,Richard Hazen,Ann Aulabaugh,(unknown)	10
17	Unique purine crossover activation pathway for the potent anti-HIV agent 1592U89 1995 ·Antiviral Research ·M B Faletto,Wayne H. Miller,Edward P. Garvey,M H St Clair,Richard Hazen,Susan M. Daluge,Steven S. Good	3
18	Trifenagrel: a chemically novel platelet aggregation inhibitor. 1989 ·Journal of Pharmacology and Experimental Therapeutics ·Sanders L. Abrahams,Richard Hazen,A. G. Batson,(unknown)	51
19	Hormonal regulation of glycogen synthase 1980 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Ronald J. Walkenbach,Richard Hazen,Joseph Larner	28
20	An absolute requirement for insulin in the control of hepatic glycogenesis by glucose 1973 ·Biochemical and Biophysical Research Communications ·Thomas B. Miller,Richard Hazen,Joseph Larner	45

About Richard Hazen

Richard Hazen is a scholar working on Virology, Infectious Diseases and Transplantation, having authored 36 papers that have together received 1.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (22 papers) and Biochemical and Molecular Research (10 papers). The work is most often cited by research in Virology (687 citations), Infectious Diseases (879 citations) and Organic Chemistry (441 citations). Richard Hazen has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Joseph Larner, Robert G. Ferris, Joseph H. Chan, Ronald J. Walkenbach, Edward P. Garvey, Lawrence R. Boone, D.K. Stammers, Karen R. Romines, Steven A. Short and C. Webster Andrews. Their work appears in journals such as Biochemical and Biophysical Research Communications, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact